Zurich Cantonal Bank
TRVI icon

Zurich Cantonal Bank’s Trevi Therapeutics TRVI Stock Holding History

Zurich Cantonal Bank’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$480K Sell
25,753
-34,109
-57% -$496K ﹤0.01% 1966
2026
Q1 		$714K Buy
59,862
+13,181
+28% +$148K ﹤0.01% 1623
2025
Q4 		$584K Buy
46,681
+21,503
+85% +$249K ﹤0.01% 1695
2025
Q3 		$230K Buy
25,178
+22,602
+877% +$169K ﹤0.01% 2128
2025
Q2 		$14.1K Sell
2,576
-305
-11% -$1.9K ﹤0.01% 2499
2025
Q1 		$18.1K Buy
+2,881
New +$13.7K ﹤0.01% 2561

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Zurich Cantonal Bank's TRVI Position: Q2 2026 in Review

Zurich Cantonal Bank reduced its Trevi Therapeutics (TRVI) stake by 57% in Q2 2026, selling an estimated $496K and leaving 25,753 shares worth $480K. The position accounts for ﹤0.01% of the portfolio, ranked #1966.

Zurich Cantonal Bank first reported a position in TRVI in Q1 2025 and has held it in 6 quarters since. The position peaked at $714K in Q1 2026. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Zurich Cantonal Bank held 25,753 shares of Trevi Therapeutics worth $480K as of Q2 2026.
  • Zurich Cantonal Bank sold 34,109 Trevi Therapeutics shares in Q2 2026, an estimated $496K.
  • Trevi Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1966 holding.
  • Zurich Cantonal Bank first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Zurich Cantonal Bank's Trevi Therapeutics position peaked at $714K in Q1 2026.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.